Acura Pharmaceuticals, Inc. has just been named to Galen Partners Investment Firm's "Top Portfolio Companies" list. In addition, Acura Pharm has just secured gross proceeds of $1,135,000 in bridge funding to continue funding product development and licensing activities relating to OxyADF™ tablets and other product candidates utilizing its Aversion® Technology.
This is a huge step for Acura Pharm with its current patents, specifically OxyADF™, currently in the FDA process. With continued support of Galen Partners and other investment firms, Acura Pharm will be on the virge of medical breakthrough leading to a boom in financial growth and the possibility of procurement by larger companies like Merck and Johnson&Johnson.
Posts: 5 | From: San Diego, CA | Registered: Jul 2006
| IP: Logged |